Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks  Timothy J. Craig, MD, Robyn J. Levy,

Slides:



Advertisements
Similar presentations
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
What drives prescription patterns in pediatric asthma management?
The natural history of soy allergy
Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients  Henriette Farkas, MD, PhD, DSc, Dorottya.
Allergen immunotherapy: A practice parameter third update
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents  James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks  Timothy J. Craig, MD, Robyn J. Levy,
Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility 
David A. Khan, MD  Journal of Allergy and Clinical Immunology 
Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients  Henriette Farkas, MD, PhD, DSc, Dorottya.
Rising prevalence of asthma is sex-specific in a US farming population
Hereditary angioedema: Safety of long-term stanozolol therapy
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J
Allergy testing in predicting outcome of open food challenge to peanut
Physician needs in health informatics: Just ask the docs
A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema 
Treatment of chronic autoimmune urticaria with omalizumab
Nonadherence to Asthma Treatment: Getting Unstuck
Peter M. Wolfgram, MD, David B. Allen, MD 
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations  Raymond G.
William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P
Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA 
Reply Journal of Allergy and Clinical Immunology
Respiratory sensitization of a worker to the warehouse beetle Trogoderma variabile: An index case report  Jonathan A. Bernstein, MD, Marjorie S. Morgan,
Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation  Leif Bjermer, MD  Journal of Allergy.
Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis  Zachary M. Soler, MD, MSc, J. Madison Hyer, MS, Luke Rudmik, MD, MSc,
Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management  Scott H. Sicherer, MD, Hugh A. Sampson, MD  Journal.
Andy Kusuma, MD, Anurag Relan, MD, André C
Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Claus Bachert, MD, PhD, Cezmi A. Akdis, MD 
What is an “eosinophilic phenotype” of asthma?
Endotyping early childhood asthma by quantitative symptom assessment
Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants  Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,
Medication use in children with asthma in Finland from 1995 to 2006
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
H. William Kelly, PharmD  Journal of Allergy and Clinical Immunology 
Autophagy: Nobel Prize 2016 and allergy and asthma research
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
Advances in the approach to the patient with food allergy
Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L
Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S
New pathways for itching in patients with atopic dermatitis?
Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF 
Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency  Marcel Levi, MD,
Reply Journal of Allergy and Clinical Immunology
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency  Richard L. Wasserman, MD, PhD,
Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J
Macrolide antibiotics and asthma treatment
Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge  Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.
Asthma: The past, future, environment, and costs
Environmental factors and eosinophilic esophagitis
The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms  Jeffrey R. Stokes, MD, Francisco A. Romero,
Negative affect, medication adherence, and asthma control in children
Safety and efficacy of repeated monthly carboplatin desensitization
Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor– associated angioedema  Scott A. Hubers, MD, Kevin Kohm, MS, Shouzuo Wei,
Natural history of cow’s milk allergy
Primary prevention of asthma and allergy
Presentation transcript:

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks  Timothy J. Craig, MD, Robyn J. Levy, MD, Richard L. Wasserman, PhD, MD, Againdra K. Bewtra, MD, David Hurewitz, MD, Krystyna Obtułowicz, MD, Avner Reshef, MD, Bruce Ritchie, MD, Dumitru Moldovan, MD, Todor Shirov, MD, Vesna Grivcheva-Panovska, MD, Peter C. Kiessling, PhD, Heinz-Otto Keinecke, MS, Jonathan A. Bernstein, MD  Journal of Allergy and Clinical Immunology  Volume 124, Issue 4, Pages 801-808 (October 2009) DOI: 10.1016/j.jaci.2009.07.017 Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Patient disposition by treatment group. Journal of Allergy and Clinical Immunology 2009 124, 801-808DOI: (10.1016/j.jaci.2009.07.017) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Kaplan-Meier curves for time to onset of symptom relief, as determined by patient assessment (intention-to-treat population). A, Values set to 24 hours if rescue medication was given before onset of symptom relief (primary analysis). Only the curves for as long as 4 hours after treatment are shown because values did not change thereafter through 24 hours after treatment. B, Actual values recorded (ie, values not set to 24 hours if rescue medication was given before onset of symptom relief). BW, Body weight. Journal of Allergy and Clinical Immunology 2009 124, 801-808DOI: (10.1016/j.jaci.2009.07.017) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions